Literature DB >> 14717670

Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers.

A M Groeger1, V Esposito, A De Luca, R Cassandro, G Tonini, V Ambrogi, F Baldi, R Goldfarb, T C Mineo, A Baldi, E Wolner.   

Abstract

AIMS: Some experimental evidence suggests that in lung cancer, development, progression and an increased proliferation rate can be linked to apoptosis-related factors. In this study we evaluated the possible role of p53 and Bcl-2 gene family members as prognostic factors for non-small-cell lung cancer. METHODS AND
RESULTS: We investigated the immunohistochemical expression of p53 and Bcl-2 gene family members (bax, Bcl-2 and Bcl-xL) in 94 non-small-cell lung cancer specimens to establish the role of these genes in lung cancer pathogenesis, and to evaluate their prognostic importance. The expression of Bcl-2 was correlated with a shorter patient survival time and with the nodal status of the neoplasm. We also found frequent over-expression of bax and Bcl-xL to be of no prognostic significance. Finally, we found no correlation between frequent detection of aberrant p53 protein and expression of either Bcl-2, bax or Bcl-xL or with patient survival time.
CONCLUSIONS: This study confirms a relevant role for apoptosis-regulatory proteins in the pathogenesis of lung cancer, and highlights the possible role of Bcl-2 as a prognostic factor for this tumour.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717670     DOI: 10.1111/j.1365-2559.2004.01750.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  26 in total

1.  The value of serum Bcl-2 levels in advanced lung cancer patients.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Hakan Camlica; Ethem Nezih Oral; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Recurrent and metastatic extragastrointestinal stromal tumors of the mesentery with C-KIT and PDGFRA mutations: a case report.

Authors:  Huang Yayu; Zhang Changmao; Dai Yijun; Lin Na; Xu Tianwen; Dai Yangbin
Journal:  Cancer Biol Ther       Date:  2019-10-10       Impact factor: 4.742

4.  TIP30 regulates apoptosis-related genes in its apoptotic signal transduction pathway.

Authors:  Mei Shi; Xia Zhang; Ping Wang; Hong-Wei Zhang; Bai-He Zhang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  A herbal medicine for the treatment of lung cancer.

Authors:  Rama S Ranga; Srinivasan Sowmyalakshmi; Ravshan Burikhanov; Mohammed A Akbarsha; Damodaran Chendil
Journal:  Mol Cell Biochem       Date:  2005-12       Impact factor: 3.396

6.  High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Authors:  Valsamo K Anagnostou; Frank J Lowery; Vassiliki Zolota; Vassiliki Tzelepi; Arun Gopinath; Camil Liceaga; Nikolaos Panagopoulos; Konstantina Frangia; Lynn Tanoue; Daniel Boffa; Scott Gettinger; Frank Detterbeck; Robert J Homer; Dimitrios Dougenis; David L Rimm; Konstantinos N Syrigos
Journal:  BMC Cancer       Date:  2010-05-09       Impact factor: 4.430

7.  Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.

Authors:  Irit Cohen; Myriam Maoz; Hagit Turm; Sorina Grisaru-Granovsky; Bella Maly; Beatrice Uziely; Einat Weiss; Rinat Abramovitch; Eithan Gross; Oded Barzilay; Yun Qiu; Rachel Bar-Shavit
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

Review 8.  Apoptosis block as a barrier to effective therapy in non small cell lung cancer.

Authors:  Ian Paul; J Mark Jones
Journal:  World J Clin Oncol       Date:  2014-10-10

9.  Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.

Authors:  Iñaki Valles; Maria J Pajares; Victor Segura; Elisabet Guruceaga; Javier Gomez-Roman; David Blanco; Akiko Tamura; Luis M Montuenga; Ruben Pio
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

10.  Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.

Authors:  Violetta Ritter; Franziska Krautter; Diana Klein; Verena Jendrossek; Justine Rudner
Journal:  Cell Death Dis       Date:  2021-07-13       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.